Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Periprosthetic Osteolysis After Total Hip Arthroplasty
NCT02299817Phase 2Unknown
- Start
- Aug 2015
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteolysis comparing Denosumab with Placebo (2 arms). Primary endpoint: Volume of the osteolytic lesion at 3 years. Status: unknown.
02
Drugs
denosumab
03
Conditions
osteolysis
Beyond the preview
Go deeper on NCT02299817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02299817.